We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+11.21%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.61B
AUM Growth
+$95.7M
Cap. Flow
-$7.31M
Cap. Flow %
-0.45%
Top 10 Hldgs %
28.48%
Holding
136
New
14
Increased
29
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
TTD icon
Trade Desk
TTD
+$22.4M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.4M
3
HUBS icon
HubSpot
HUBS
+$14M
4
AIMT
Aimmune Therapeutics
AIMT
+$13.7M
5
APTV icon
Aptiv
APTV
+$13.2M

Top Sells

Rank Stock Value
1
ROL icon
Rollins
ROL
+$21.9M
2
AYI icon
Acuity Brands
AYI
+$17.5M
3
LRCX icon
Lam Research
LRCX
+$14.7M
4
OPLN
Openlane
OPLN
+$13.9M
5
XPO icon
XPO
XPO
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 35.06%
2 Technology 14.25%
3 Consumer Discretionary 14.02%
4 Industrials 8.96%
5 Utilities 4.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TTPH
76
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$4.28M 0.27%
30,000
– –
EPZM
77
DELISTED
Epizyme, Inc
EPZM
$4.15M 0.26%
275,000
– –
LKFT
78
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$3.98M 0.25%
52,000
– –
ACHN
79
DELISTED
Achillion Pharmaceuticals
ACHN
$3.9M 0.24%
850,000
+250,000
+42% +$1M
ACRS icon
80
Aclaris Therapeutics
ACRS
$743M
$3.8M 0.24%
140,000
– –
REGN icon
81
Regeneron Pharmaceuticals
REGN
$77.4B
$3.68M 0.23%
+7,500
New +$3.28M
TSRO
82
DELISTED
TESARO, Inc.
TSRO
$3.64M 0.23%
26,000
– –
IRWD icon
83
Ironwood Pharmaceuticals
IRWD
$614M
$3.63M 0.23%
+229,248
New +$3.33M
DERM
84
DELISTED
Dermira, Inc.
DERM
$3.61M 0.22%
+124,000
New +$3.77M
RXDX
85
DELISTED
Ignyta, Inc.
RXDX
$3.56M 0.22%
+344,000
New +$2.79M
EXAS
86
DELISTED
Exact Sciences
EXAS
$3.54M 0.22%
+100,000
New +$3.09M
SNDX icon
87
Syndax Pharmaceuticals
SNDX
$1.73B
$3.14M 0.2%
+225,000
New +$2.57M
NTUS
88
DELISTED
Natus Medical Inc
NTUS
$2.8M 0.17%
75,000
– –
VYGR icon
89
Voyager Therapeutics
VYGR
$189M
$2.69M 0.17%
300,000
– –
MGNX icon
90
MacroGenics
MGNX
$240M
$2.57M 0.16%
147,000
– –
NGNE icon
91
Neurogene
NGNE
$670M
$2.46M 0.15%
8,750
– –
SYRS
92
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.41M 0.15%
15,000
– –
CTMX icon
93
CytomX Therapeutics
CTMX
$714M
$2.33M 0.14%
150,000
– –
SEP
94
DELISTED
Spectra Engy Parters Lp
SEP
$2.25M 0.14%
52,500
+14,500
+38% +$631K
TCON
95
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$2.16M 0.13%
4,500
– –
CHRS icon
96
Coherus Oncology
CHRS
$227M
$2.08M 0.13%
145,000
– –
CDTX
97
DELISTED
Cidara Therapeutics
CDTX
$1.98M 0.12%
13,200
– –
RARX
98
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.87M 0.12%
+100,000
New +$2.26M
JCI icon
99
Johnson Controls International
JCI
$87.8B
$1.78M 0.11%
41,000
+11,500
+39% +$481K
ABB
100
DELISTED
ABB Ltd
ABB
$1.69M 0.11%
68,000
+17,500
+35% +$429K
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2017 Portfolio in Review

As of Q2 2017, Eventide Asset Management held 136 positions worth $1.61B, up 6.3% from $1.51B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Eventide Asset Management's Q2 2017 filing shows 14 new, 29 increased, 19 reduced and 10 closed positions. Its largest new stake was Trade Desk: 4,900,000 shares worth $24.6M. The largest sale was Rollins, an estimated $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q2 2017 buy was Trade Desk: 4,900,000 shares worth $24.6M.
  • Eventide Asset Management added most to AveXis, Inc. Common Stock in Q2 2017, an estimated $19.4M increase.
  • Eventide Asset Management's biggest Q2 2017 reduction was Acuity Brands, cutting an estimated $17.5M.
  • Eventide Asset Management fully exited Rollins in Q2 2017, selling an estimated $21.9M.
  • Eventide Asset Management's ten largest holdings make up 28% of its $1.61B portfolio in Q2 2017.
  • Eventide Asset Management opened 14 new positions and closed 10 in Q2 2017.
  • Eventide Asset Management's portfolio value rose 6.3% quarter-over-quarter to $1.61B.

Based on Eventide Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.